MEREO BIOPHARMA GROUP PLC Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount
MEREO BIOPHARMA GROUP PLC (MREO) had Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount of $4.00 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized · last filed 2026-08-11
- 2026-06-30: Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount $4.00M.
- 2026-03-31: Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount $5.50M.
- 2025-12-31: Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount $4.30M.
- 2025-09-30: Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount $5.70M.
| Period end | Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount |
|---|---|
| 2026-06-30 | $4.00M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $5.50M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $4.30M 10-K · filed 2026-03-19 |
| 2025-09-30 | $5.70M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $6.90M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $9.80M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $4.10M 10-K · filed 2025-03-26 |
| 2024-09-30 | $5.60M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $7.30M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $9.30M 10-Q · filed 2024-05-15 |
| 2023-12-31 | $2.90M 10-K · filed 2024-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |